Why Is NURIX THERAPEUTICS I (NRIX) Stock Up Today?
By the Top Tier Newswire AI Desk · reviewed against 8 wire stories
NURIX THERAPEUTICS I (NRIX) is up +4.47% in the latest session. Our newswire has captured 8 stories on NRIX across 4 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
The written analysis for NRIX publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.
AI sentiment, last 36h · averaged over 8 stories · 56/100 bullish
The headlines behind the move
Story flow · 7 stories on the wire, last 36h · hover or tap a dot for the headline
4h agoSeeking AlphaBULLISH 74Analyst
Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways
Nurix Therapeutics is a strong buy due to pivotal progress with bexobrutideg, robust partnerships, and strong financials. Read more on NRIX stock here.
1d agoThe FlyBEARISH 38Analyst
Nurix Therapeutics price target lowered to $33 from $34 at Truist
1d agoThe FlyBEARISH 38Analyst
Nurix Therapeutics price target lowered to $35 from $36 at RBC Capital
1d agoThe FlyBULLISH 64Analyst
Nurix Therapeutics price target raised to $32 from $28 at Oppenheimer
1d agoThe FlyBULLISH 64Analyst
Nurix Therapeutics price target raised to $36 from $33 at Baird
1d agoThe FlyBULLISH 63Analyst
Nurix Therapeutics price target raised to $41 from $40 at Stifel
1d agoSEC 8-KNEUTRAL 50General
Nurix Therapeutics, Inc. (NRIX) files 8-K
Filed: 2026-10-13 AccNo: 0001549595-26-000048 Size: 268 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
1d agoGlobeNewswireBULLISH 58Earnings
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced bexobrutideg combination strategy with initiation...
Frequently asked questions
Why is NRIX stock up today?
NURIX THERAPEUTICS I (NRIX) is up +4.47% in the latest session. Our newswire has captured 8 stories on NRIX across 4 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100). The most recent driver: "Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways" (Seeking Alpha).
Is NRIX a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of NRIX coverage reads 56/100 over 8 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →